Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.6K
Abnormal Proliferation02:23

Abnormal Proliferation

5.0K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.0K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

6.9K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.9K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Replicative Cell Senescence02:15

Replicative Cell Senescence

4.3K
Replicative cell senescence is a property of cells that allows them to divide a finite number of times throughout the organism's lifespan while preventing excessive proliferation. Replicative senescence is associated with the gradual loss of the telomere — short, repetitive DNA sequences found at the end of the chromosomes. Telomeres are bound by a group of proteins to form a protective cap on the ends of chromosomes. Embryonic stem cells express telomerase — an enzyme that adds...
4.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Host-derived Limosilactobacillus reuteri supplementation improves piglet growth and gut integrity in heat-stressed sows.

Veterinary research communications·2026
Same author

A Review on the Current Research and Industrialization Status of Edible Insect Protein.

Food science of animal resources·2026
Same author

Synergy of a Low-methionine Diet and Reduced-dose Cisplatinum Eradicates Experimental Lung-cancer Bone Metastases in a Nude-mouse Model.

In vivo (Athens, Greece)·2026
Same author

Direct comparison of efficacy of combining ivermectin versus five first-line chemotherapy drugs with recombinant methioninase against colon-cancer cells.

Frontiers in oncology·2026
Same author

Osteoporosis in long-term hospitalized patients with muscular dystrophy: a retrospective cross-sectional study.

BMC musculoskeletal disorders·2026
Same author

Dietary β-mannanase supplementation and its effect on nutrient utilization and performance in broilers fed energy-reduced diets.

Food science of animal resources·2026

Related Experiment Video

Updated: Jan 7, 2026

Monitoring the Cancer-Immunity Cycle and Exploring Tumor Microenvironment Dynamics
12:19

Monitoring the Cancer-Immunity Cycle and Exploring Tumor Microenvironment Dynamics

Published on: June 7, 2024

1.9K

Methionine Restriction Must Be Continuously Maintained to Selectively Inhibit Cancer Cells Co-cultured With Normal

Byung Mo Kang1,2, Qinghong Han1, Shukuan Li1

  • 1AntiCancer Inc., San Diego, CA, U.S.A.

Cancer Diagnosis & Prognosis
|January 5, 2026
PubMed
Summary
This summary is machine-generated.

Methionine restriction using recombinant methioninase (rMETase) inhibits colon cancer cells. Replenishing methionine allows cancer cells to regrow, highlighting the need for continuous methionine restriction to control cancer.

Keywords:
Cancer cellsHoffman effectco-culturemethionine addictionmethionine rescuenormal fibroblastsrecombinant methioninaseselective cancer efficacy

More Related Videos

Modeling Chemotherapy Resistant Leukemia In Vitro
08:41

Modeling Chemotherapy Resistant Leukemia In Vitro

Published on: February 9, 2016

9.5K
Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module
10:39

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module

Published on: June 18, 2015

13.8K

Related Experiment Videos

Last Updated: Jan 7, 2026

Monitoring the Cancer-Immunity Cycle and Exploring Tumor Microenvironment Dynamics
12:19

Monitoring the Cancer-Immunity Cycle and Exploring Tumor Microenvironment Dynamics

Published on: June 7, 2024

1.9K
Modeling Chemotherapy Resistant Leukemia In Vitro
08:41

Modeling Chemotherapy Resistant Leukemia In Vitro

Published on: February 9, 2016

9.5K
Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module
10:39

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module

Published on: June 18, 2015

13.8K

Area of Science:

  • Oncology
  • Biochemistry
  • Cell Biology

Background:

  • Methionine addiction is a cancer hallmark targeted by methionine restriction.
  • Recombinant methioninase (rMETase) depletes methionine, affecting cancer cells.
  • Previous studies indicated differential sensitivity of cancer cells and normal fibroblasts to rMETase.

Purpose of the Study:

  • To investigate the rescue conditions for cancer cells upon methionine replenishment after rMETase treatment.
  • To evaluate the impact of methionine replenishment on co-cultures of HCT-116 colon cancer cells and Hs27 normal fibroblasts.

Main Methods:

  • Co-culturing HCT-116 colon cancer cells and Hs27 normal fibroblasts.
  • Treating co-cultures with rMETase at the HCT-116 IC50 or using untreated controls.
  • Monitoring cell growth via phase-contrast microscopy over 12 days.
  • Replenishing methionine on day 12 and assessing subsequent cell regrowth.

Main Results:

  • Untreated HCT-116 cells outcompeted Hs27 cells by day 12.
  • rMETase treatment led to a near-complete elimination of HCT-116 cells by day 12, while Hs27 cells survived.
  • Methionine replenishment on day 12 resulted in the reappearance and subsequent dominance of HCT-116 cells by day 9.

Conclusions:

  • Continuous rMETase treatment is essential to maintain cancer cell inhibition and normal cell dominance.
  • Methionine restriction must be continually maintained to effectively inhibit cancer growth.
  • These findings have clinical implications for cancer therapy involving methionine restriction.